leadf
logo-loader
viewRedHill Biopharma

Redhill BioPharma presents at the Proactive One2One virtual conference

RedHill Biopharma Ltd's (Nasdaq: RDHL) Guy Goldberg pitches to investors at the Proactive One2One virtual conference.

The company is a specialty biopharmaceutical company focussed on gastrointestinal and infectious diseases.

They promote several GI drugs in the U.S with a robust late-stage development pipeline.

Quick facts: RedHill Biopharma

Price: 8.85 USD

NASDAQ:RDHL
Market: NASDAQ
Market Cap: $333.6 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of RedHill Biopharma named herein, including the promotion by the Company of RedHill Biopharma in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Redhill Biopharma's Opaganib 'one of most advanced, novel investigational...

RedHill Biopharma Ltd's (Nasdaq: RDHL) Guy Goldberg talks to Proactive London about their operations, which include working towards a remedy for Covid-19 with Opaganib. Goldberg describes the drug as 'one of most advantaged, novel investigational Covid-19 drugs'. Opaganib is orally-taken,...

on 10/09/2020

2 min read